Abstract
Background Reliable biomarkers for precision medicine in metastatic colorectal cancer (mCRC) are needed. Blood biomarkers like chemokines may offer insights into overall tumor burden, yet, few prospective studies explore chemokine dynamics during treatment. This study investigates the behavior of a chemokine panel in mCRC patients during first-line oxaliplatin-based treatment, aiming to identify predictive and prognostic biomarkers.
Methods Blood from oxaliplatin-treated mCRC patients was collected at three time points: before treatment (PRET), at response evaluation (EVAR), and at disease progression or last follow-up (LFUP). A custom 11-chemokine panel assessed serum chemokine levels by Luminex®, correlating them with treatment response, overall survival (OS), and progression-free survival (PFS) using the Cox proportional hazards models with the inverse probability weighting (IPW) approach. Additionally, immune system-associated gene expression was studied by Nanostring® in 15 primary tumor samples and correlated with CXCL13 expression, OS, and PFS. In silico analysis of 119 liver metastases from CRC patients, post neoadjuvant oxaliplatin-based treatment or untreated, evaluated CXCL13 expression’s correlation with immune cell infiltration, tertiary lymphoid structure (TLS) presence, OS, and PFS. Additionally, CXCL13 dynamics was studied by ELISA in 36 mCRC patients from the METIMMOX study control arm.
Results Responders exhibited increased CXCL13 at EVAR, contrasting with non-responders whose levels decreased at EVAR and LFUP. Increased CXCL13 independently associated with improved PFS (median 14.5 vs. 8.9 months; HR = 0.34, p = 0.003) and OS (median 39.7 vs. 15.3 months; HR = 0.34, p = 0.003). CXCL13 expression correlated positively with an immunogenic tumor microenvironment, increased B cells, T cells (mainly CD8+) and enhanced OS. In silico, higher CXCL13 expression associated significantly with increased immune infiltration and improved OS. High CXCL13 expression was linked to the presence of TLSs, also associated with enhanced OS, especially in neoadjuvant-treated patients. Similar trends were obtained using the METIMMOX cohort.
Conclusion The increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in metastatic CRC patients undergoing oxaliplatin-based treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded by the ISCIII grant from the Spanish Government, project number PI16/01800 and the Departament d’Innovació , Universitats i Empresa, Generalitat de Catalunya, project number 2017-SGR-723, both of them awarded to Dr. Martinez-Balibrea and it is based in part upon work from COST Action CA21135, supported by COST (European Cooperation in Science and Technology). Dr. Pilar Navarro was supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/ Instituto de Salud Carlos III (ISCIII)-FEDER (PI20/00625 and PI23/00591). Ferran Grau-Leal is supported by an AGAUR-FI grant (2023 FI-3 00065) from the predoctoral program Joan Oró of the Secretaria d’Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya and the European Social Funds Plus. Carla Vendrell-Ayats holds an INVESTIGO program contract from the Generalitat de Catalunya, funded by the EU, Next Generation European Funds. Miguel Angel Pardo-Cea was supported by a PERIS PFI-Salut SLT017-20-000076 grant from the Generalitat de Catalunya; METIMMOX study was funded by the Norwegian Cancer Society, including its Umbrella Foundation for Cancer Research, grants 182496 and 215613 and the South-Eastern Norway Regional Health Authority grants 2018054. Anne Hansen Ree received research support from Bristol-Myers Squibb (on behalf of Akershus University Hospital).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the Ethics Committee of Germans Trias I Pujol University Hospital under the internal reference number IP-16-115. All patients received proper information and signed the corresponding informed consent
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
